Compare Stocks: ONCY, AKBA, ELYM, and CMPX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKBA Akebia Therapeutics	$0.91 -4.7%	$1.16	$0.82 ▼ $3.44	$256.03M	0.26	3.27 million shs	10.93 million shs
CMPX Compass Therapeutics	$2.15 +8.0%	$2.09	$1.61 ▼ $6.88	$358.38M	0.92	2.66 million shs	3.83 million shs
ELYM Eliem Therapeutics	$14.00	$12.29	$2.35 ▼ $11.55	$416.53M	-0.39	486,688 shs	910,274 shs
ONCY Oncolytics Biotech	$0.80 +0.2%	$0.87	$0.73 ▼ $1.51	$95.56M	1.13	1.43 million shs	566,366 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKBA Akebia Therapeutics	-4.66%	-31.07%	-35.92%	-21.56%	-75.99%
CMPX Compass Therapeutics	+8.04%	+12.57%	-8.12%	+17.49%	-26.12%
ELYM Eliem Therapeutics	+12.27%	+15.89%	+4.32%	+23.13%	+723.53%
ONCY Oncolytics Biotech	+0.24%	+6.53%	+1.29%	-9.82%	-13.71%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKBA Akebia Therapeutics	$0.91 -4.7%	$1.16	$0.82 ▼ $3.44	$256.03M	0.26	3.27 million shs	10.93 million shs
CMPX Compass Therapeutics	$2.15 +8.0%	$2.09	$1.61 ▼ $6.88	$358.38M	0.92	2.66 million shs	3.83 million shs
ELYM Eliem Therapeutics	$14.00	$12.29	$2.35 ▼ $11.55	$416.53M	-0.39	486,688 shs	910,274 shs
ONCY Oncolytics Biotech	$0.80 +0.2%	$0.87	$0.73 ▼ $1.51	$95.56M	1.13	1.43 million shs	566,366 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKBA Akebia Therapeutics	-4.66%	-31.07%	-35.92%	-21.56%	-75.99%
CMPX Compass Therapeutics	+8.04%	+12.57%	-8.12%	+17.49%	-26.12%
ELYM Eliem Therapeutics	+12.27%	+15.89%	+4.32%	+23.13%	+723.53%
ONCY Oncolytics Biotech	+0.24%	+6.53%	+1.29%	-9.82%	-13.71%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKBA Akebia Therapeutics	2.33	Hold	$3.75	312.13% Upside
CMPX Compass Therapeutics	2.88	Moderate Buy	$11.77	447.41% Upside
ELYM Eliem Therapeutics	0.00	N/A	N/A	N/A
ONCY Oncolytics Biotech	2.75	Moderate Buy	$8.50	959.19% Upside

Current Analyst Ratings Breakdown

Latest ONCY, AKBA, ELYM, and CMPX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2026	AKBA Akebia Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$1.00
8/7/2026	CMPX Compass Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$4.00 ➝ $6.00
8/6/2026	AKBA Akebia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/3/2026	AKBA Akebia Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	CMPX Compass Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/14/2026	ONCY Oncolytics Biotech	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/13/2026	ONCY Oncolytics Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/7/2026	AKBA Akebia Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/1/2026	AKBA Akebia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$6.00
7/1/2026	CMPX Compass Therapeutics	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$5.00
6/25/2026	ONCY Oncolytics Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 8/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKBA Akebia Therapeutics	$219.06M	1.11	N/A	N/A	$0.09 per share	10.11
CMPX Compass Therapeutics	$850K	455.52	N/A	N/A	$1.11 per share	1.94
ELYM Eliem Therapeutics	N/A	N/A	N/A	N/A	$3.90 per share	N/A
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	($0.04) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKBA Akebia Therapeutics	-$5.34M	-$0.11	N/A	N/A	N/A	-13.54%	-88.88%	-7.74%	N/A
CMPX Compass Therapeutics	-$66.49M	-$0.41	N/A	N/A	N/A	N/A	-37.16%	-33.59%	N/A
ELYM Eliem Therapeutics	-$35.12M	-$0.53	N/A	N/A	N/A	N/A	-47.03%	-45.97%	N/A
ONCY Oncolytics Biotech	-$28.76M	-$0.31	N/A	N/A	N/A	N/A	-2,185.97%	-321.54%	8/14/2026 (Estimated)

Latest ONCY, AKBA, ELYM, and CMPX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	CMPX Compass Therapeutics	-$0.1107	-$0.13	-$0.0193	-$0.13	($0.60) million	N/A
8/5/2026	Q2 2026	AKBA Akebia Therapeutics	-$0.0420	-$0.02	+$0.0220	-$0.03	$48.85 million	$49.13 million
5/14/2026	Q1 2026	ONCY Oncolytics Biotech	-$0.05	-$0.08	-$0.03	-$0.08	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKBA Akebia Therapeutics	N/A	N/A	N/A	N/A	N/A
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A
ELYM Eliem Therapeutics	N/A	N/A	N/A	N/A	N/A
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKBA Akebia Therapeutics	0.99	1.43	1.33
CMPX Compass Therapeutics	N/A	19.04	19.04
ELYM Eliem Therapeutics	N/A	60.41	60.41
ONCY Oncolytics Biotech	N/A	1.38	1.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKBA Akebia Therapeutics	33.92%
CMPX Compass Therapeutics	68.43%
ELYM Eliem Therapeutics	69.76%
ONCY Oncolytics Biotech	6.82%

Insider Ownership

Company	Insider Ownership
AKBA Akebia Therapeutics	4.30%
CMPX Compass Therapeutics	18.70%
ELYM Eliem Therapeutics	4.70%
ONCY Oncolytics Biotech	0.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKBA Akebia Therapeutics	430	268.26 million	256.72 million	Optionable
CMPX Compass Therapeutics	20	180.09 million	146.41 million	Not Optionable
ELYM Eliem Therapeutics	9	29.75 million	28.35 million	Not Optionable
ONCY Oncolytics Biotech	30	119.35 million	119.24 million	Not Optionable

ONCY, AKBA, ELYM, and CMPX Headlines

Recent News About These Companies

Oncolytics Biotech (ONCY) to Post Earnings on Friday

August 7 at 1:26 AM | americanbankingnews.com

Oncolytics Biotech (ONCY) Expected to Post Quarterly Earnings on Friday

August 7 at 1:25 AM | marketbeat.com

Oncolytics Biotech (NASDAQ:ONCY) Trading Up 0.2% - Time to Buy?

July 31, 2026 | marketbeat.com

Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer

July 20, 2026 | globenewswire.com

ONCY: Seeking Registration Pathway for Part B of REO 033 Trial

July 16, 2026 | finance.yahoo.com

Oncolytics Biotech Announces Rapid REO 033 Site Activation and FDA Meeting on Registrational Pathway for Pelareorep in Metastatic Colorectal Cancer

July 13, 2026 | quiverquant.comQ

Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial

July 13, 2026 | globenewswire.com

Oncolytics Biotech (NASDAQ:ONCY) Shares Up 16.1% - What's Next?

July 9, 2026 | marketbeat.com

Oncolytics Biotech Secures New Pelareorep Manufacturing Patent

June 16, 2026 | tipranks.com

Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044

June 16, 2026 | globenewswire.com

Oncolytics Biotech (ONCY) Valuation Check As New Pelareorep RAS Combo Data Draws Investor Attention

June 5, 2026 | finance.yahoo.com

Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer

June 2, 2026 | globenewswire.com

ONCY stock heads for sixth straight session of gains – lead therapy shines in early combination treatment study

June 1, 2026 | msn.com

Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches

June 1, 2026 | globenewswire.com

Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep's Potential Across Gastrointestinal Tumors

May 22, 2026 | globenewswire.com

ONCY: Aligns with FDA on pivotal trial for Pelareorep in anal cancer

May 19, 2026 | msn.com

Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer

May 4, 2026 | globenewswire.com

Oncolytics Biotech, Inc.: Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study

April 27, 2026 | finanznachrichten.de

Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study

April 27, 2026 | globenewswire.com

Oncolytics Could Re-Rate As Pelareorep Focuses On Registrational Paths

April 25, 2026 | seekingalpha.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: ArriVent BioPharma, Inc. (AVBP) and Oncolytics Biotech (ONCY)

April 12, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCY, AKBA, ELYM, and CMPX Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

$0.91 -0.04 (-4.66%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$0.91 +0.00 (+0.12%)

As of 08/7/2026 07:56 PM Eastern

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Compass Therapeutics NASDAQ:CMPX

$2.15 +0.16 (+8.04%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$2.12 -0.02 (-1.16%)

As of 08/7/2026 07:45 PM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Eliem Therapeutics NASDAQ:ELYM

$14.00 0.00 (0.00%)

As of 08/7/2026

Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Oncolytics Biotech NASDAQ:ONCY

$0.80 +0.00 (+0.24%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$0.81 +0.01 (+1.18%)

As of 08/7/2026 07:56 PM Eastern

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ONCY, AKBA, ELYM, and CMPX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ONCY, AKBA, ELYM, and CMPX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ONCY, AKBA, ELYM, and CMPX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCY, AKBA, ELYM, and CMPX Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

Compass Therapeutics NASDAQ:CMPX

Eliem Therapeutics NASDAQ:ELYM

Oncolytics Biotech NASDAQ:ONCY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ONCY, AKBA, ELYM, and CMPX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ONCY, AKBA, ELYM, and CMPX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ONCY, AKBA, ELYM, and CMPX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCY, AKBA, ELYM, and CMPX Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

Compass Therapeutics NASDAQ:CMPX

Eliem Therapeutics NASDAQ:ELYM

Oncolytics Biotech NASDAQ:ONCY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools